Early toxicity in a prospective phase I/II trial of MRI-assisted focal boost integrated with HDR monotherapy for low- and intermediate-risk prostate cancer.

被引：0
|
作者：
D'alimonte, Laura
Helou, Joelle Antoine
Morton, Gerard
Chung, Hans T.
McGuffin, Merrylee
Ravi, Ananth
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 06期
关键词：
D O I：
10.1200/JCO.2017.35.6_suppl.120
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
120
引用
收藏
页数：1
相关论文
共 50 条
  • [1] MRI assisted focal boost integrated with HDR monotherapy for low/intermediate risk prostate cancer
    Dalimonte, L.
    Helou, J.
    Morton, G.
    Chung, H.
    McGuffin, M.
    Ravi, A.
    Loblaw, A.
    RADIOTHERAPY AND ONCOLOGY, 2017, 123 : S51 - S51
  • [2] MRI assisted focal boost integrated with HDR monotherapy study in low and intermediate risk prostate cancer (MARS): Results from a phase II clinical trial
    Alayed, Yasir
    D'Alimonte, Laura
    Helou, Joelle
    Ravi, Ananth
    Morton, Gerard
    Chung, Hans T.
    Haider, Masoom
    McGuffin, Merrylee
    Zhang, Liying
    Loblaw, Andrew
    RADIOTHERAPY AND ONCOLOGY, 2019, 141 : 144 - 148
  • [3] Early toxicity in a randomized trial of high dose-rate (HDR) brachytherapy as monotherapy for low- and intermediate-risk prostate cancer.
    Morton, Gerard
    Chung, Hans T.
    McGuffin, Merrylee
    Zhang, Liying
    Ravi, Ananth
    D'Alimonte, Laura
    Loblaw, Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [4] Toxicity and Quality of Life Outcomes from a Randomized Phase II Trial of HDR Monotherapy for Low and Intermediate-Risk Prostate Cancer
    Hasan, Y.
    Loblaw, D. A.
    Chung, H. R.
    McGuffin, M.
    Tseng, C. L.
    Mendez, L. C.
    Ravi, A.
    Zhang, L.
    Mamedov, A.
    Morton, G.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : S133 - S133
  • [5] TOXICITY AND QUALITY OF LIFE RESULTS FROM A RANDOMIZED PHASE II TRIAL OF HDR MONOTHERAPY FOR LOW AND INTERMEDIATE-RISK PROSTATE CANCER
    Hasan, Yaser
    Loblaw, Andrew
    Chung, Hans
    McGuffin, Merrylee
    Tseng, Chia-Lin
    Mendez, Lucas
    Ravi, Ananth
    Zhang, Liying
    Mamedov, Alexandre
    Morton, Gerard
    RADIOTHERAPY AND ONCOLOGY, 2019, 139 : S36 - S36
  • [6] Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results
    Aluwini, Shafak
    van Rooij, Peter
    Hoogeman, Mischa
    Kirkels, Wim
    Kolkman-Deurloo, Inger-Karine
    Bangma, Chris
    RADIATION ONCOLOGY, 2013, 8
  • [7] Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results
    Shafak Aluwini
    Peter van Rooij
    Mischa Hoogeman
    Wim Kirkels
    Inger-Karine Kolkman-Deurloo
    Chris Bangma
    Radiation Oncology, 8
  • [8] Randomized phase II trial of IGRT with or without HDR boost in intermediate-risk prostate cancer
    Vigneault, E.
    Morton, G.
    Perulekar, W.
    Niazi, T.
    Springer, G.
    Barkati, M.
    Chung, P.
    Koll, W.
    Kamran, A.
    Montreal, M.
    Ding, K.
    Loblaw, A.
    RADIOTHERAPY AND ONCOLOGY, 2017, 123 : S975 - S976
  • [9] HDR Brachytherapy as Monotherapy for Prostate Cancer: Early Toxicity of a Randomized Phase II Trial
    Jolicoeur, M.
    Derashodian, T.
    Nguyen-Huynh, T.
    Hillmann, E. de Castro
    Berbiche, D.
    Truchon, D.
    Heliou, R.
    Mondat, M.
    RADIOTHERAPY AND ONCOLOGY, 2021, 158 : S90 - S91
  • [10] SBRT in low- and intermediate-risk prostate cancer: results of a phase II study
    D'Agostino, G.
    Villa, E.
    Franzese, C.
    Liardo, R.
    Reggiori, G.
    Navarria, P.
    Iftode, C.
    De Rose, F.
    Franceschini, D.
    Tozzi, A.
    Comito, T.
    Ascolese, A.
    Tomatis, S.
    Scorsetti, M.
    RADIOTHERAPY AND ONCOLOGY, 2016, 119 : S628 - S629
12345